Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238)
The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.
Age
15 - No limit years
Sex
ALL
Healthy Volunteers
No
Local Institution - 0036
Little Rock, Arkansas, United States
Local Institution - 0117
La Jolla, California, United States
Local Institution - 0189
Los Angeles, California, United States
Local Institution - 0021
San Francisco, California, United States
Local Institution - 0006
San Francisco, California, United States
Local Institution - 0010
Aurora, Colorado, United States
Local Institution - 0004
Washington D.C., District of Columbia, United States
Local Institution - 0012
Jacksonville, Florida, United States
Local Institution - 0019
Miami Beach, Florida, United States
Local Institution - 0030
Orlando, Florida, United States
Start Date
March 16, 2015
Primary Completion Date
November 26, 2018
Completion Date
October 16, 2024
Last Updated
April 24, 2025
906
ACTUAL participants
Ipilimumab
DRUG
Nivolumab
DRUG
Placebo matching Ipilimumab
OTHER
Placebo matching Nivolumab
OTHER
Lead Sponsor
Bristol-Myers Squibb
Collaborators
NCT06066138
NCT05039801
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions